跳到正文
>hotmap_
只看一手#论文/研究
11月6日周五
  1. EMA · What's New

    儿科学：Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 6, Status: Authorised

    原文摘录：Yorvipath RSS Authorised This medicine is authorised for use in the European Union palopegteriparatide Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Yorvipath is a hormone replacement medicine fo … 37 KB - PDF) First published: 15/09/2023 View News on Yorvipath Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 15/09/2023 More information on Yorvipath EU/3/20/2350 - orphan designation for treatment of hypoparathyroidism EMA/PE/0000241327 - paediatric investigation plan A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) - post-authorisation study A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding - post-authorisation study This page was last updated on 06/11/2026

  2. EMA · What's New

    神经内科：Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Date of authorisation: 09/06/2003, Revision: 28, Status: Authorised

    原文摘录：Aldurazyme RSS Authorised This medicine is authorised for use in the European Union laronidase Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview This is a summary of the European public assessment re … This page was last updated on 06/11/2026

  3. EMA · What's New

    感染病学：Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 34, Status: Authorised

    原文摘录：Entyvio RSS Authorised This medicine is authorised for use in the European Union vedolizumab Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Entyvio is a medicine used to treat adult patients with … 73 KB - PDF) First published: 21/03/2014 Last updated: 21/03/2014 View News on Entyvio Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021 17/12/2021 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020 28/02/2020 European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014 10/07/2014 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 March 2014 21/03/2014 European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohn's disease 21/03/2014 More information on Entyvio EMEA-000645-PIP03-18 - paediatric investigation plan EMEA-000645-PIP01-09-M09 - paediatric investigation plan EMEA-000645-PIP04-20-M02 - paediatric investigation plan Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025 - post-authorisation study Vedolizumab-5001: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry - post-authorisation study Vedolizumab-5056: Clinical Effectiveness of Vedolizumab Used in Frames of Drug Program for Crohn’s Disease Treatment in Poland – Prospective, Observational Study Considering Fatigue and Other Patient-reported-outcomes (PROs) (POLONEZ II) - post-authorisation study Comparative Effectiveness of Tofacitinib Versus Ustekinumab and Vedolizumab among Ulcerative Colitis Patients With Prior Anti- Tumor Necrosis Factor (TNF) Failure - post-authorisation study Topics Medicines This page was last updated on 06/11/2026

  4. EMA · What's New

    急诊与重症医学：Human medicines European public assessment report (EPAR): Elaprase, idursulfase, Date of authorisation: 08/01/2007, Revision: 29, Status: Authorised

    原文摘录：Elaprase RSS Authorised This medicine is authorised for use in the European Union idursulfase Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview This is a summary of the European public assessment rep … This page was last updated on 06/11/2026

  6. ClinicalTrials.gov API v2 · 登记更新

    肿瘤学：Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    原文摘录：This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory).

    关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。

11月4日周三
  1. WHO · Official News OData

    内分泌与代谢：One in four adolescents worldwide reported no active days in the previous week

    原文摘录：One in four adolescents worldwide reported not getting at least 60 minutes of physical activity on any day in the previous week. … Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide

    关注理由：这条内分泌与代谢资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。

  2. WHO · Official News OData

    感染病学：Progress against neglected tropical diseases requires sustained action

    原文摘录：WHO / Monika Mey Local health workers in Cambodia are trained in surveillance techniques, including stool examination using Kato-Katz, to detect schistosomiasis eggs, identify potential hotspots and support early detection and treatment. … int Related Global report on neglected tropical diseases 2026 Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030 WHO's work on neglected tropical diseases More WHO Global Neglected Tropical Diseases Programme

    关注理由：关于感染病学的这条内容有明确出处，主要发现和适用人群可在原文中继续核查。

11月3日周二
  1. WHO · Disease Outbreak News OData

    神经内科：Shamonda virus in human - France

    原文摘录：See all DONs related to this event Situation at a glance On 20 October 2026, the National IHR Focal Point (NFP) of France notified WHO regarding the first documented human infection with Shamonda virus (SHAV). … item/2026-DON623

    关注理由：这篇神经内科资料可用于了解领域进展，研究设计、结果和局限性值得一起阅读。

11月2日周一
  1. FDA · MedWatch Safety Alerts

    肾脏病学：Early Alert: B. Braun Medical Inc. Removes Streamline Bloodline Set for Dialog+

    原文摘录：CDRH is issuing this Early Alert to notify the public of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. Affected Product The FDA is aware that B. … Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    关注理由：这条肾脏病学资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。

10月30日周五
  1. EMA · News and Safety Reviews

    精神医学：Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026

    原文摘录：Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026 30 October 2026 PRAC starts review of depression and anxiety medicine Deanxit and a safety signal related to hu … eu All other enquiries please submit your request via the online form Follow us on Bluesky Related medicine information Flupentixol/melitracen-containing medicinal products - referral Topics Pharmacovigilance

    关注理由：如果关注精神医学，这篇内容值得阅读其研究对象、方法设计和主要发现。

  2. FDA · MedWatch Safety Alerts

    血液病学：Platelet Factor 4 (PF4) Radioimmunoassay Recall: Instrumentation Laboratories Removes HemosIL AcuStar HIT-IgG(PF4-H)

    原文摘录：This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. … Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    关注理由：这篇血液病学资料可用于了解领域进展，研究设计、结果和局限性值得一起阅读。

10月23日周五
  1. EMA · News and Safety Reviews

    儿科学：AMA and EMA issue joint guidance on Ebola vaccine development

    原文摘录：Image credit: © peterschreiber.media | stock.adobe.com AMA and EMA issue joint guidance on Ebola vaccine development 23 October 2026 Clinical trial requirements defined for rapid development of Bundibugyo virus vaccines News Human Clinical trials Research … eu All other enquiries Please submit your request via the online form

    关注理由：这条儿科学资料涉及临床试验，入组条件、对照设置和研究阶段可以帮助判断结果适用于哪些人群。

10月20日周二
  1. FDA · MedWatch Safety Alerts

    呼吸病学：Update: Import Alert for Certain Olympus Medical Devices Manufactured in Japan - Letter to Health Care Providers

    原文摘录：October 20, 2026 The U.S. Food and Drug Administration (FDA) is alerting health care providers about an import alert for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation (Olympus) and its subsidiaries. … Additional Resources Import Alert 89-04 [10/19/2026] FDA Issues Two Warning Letters to Leading Manufacturer of Endoscopes [01/10/2023] Warning Letters Olympus Medical Systems Corporation Warning Letter [10/07/2026] Olympus Medical Systems Corporation Warning Letter (Hinode) [03/15/2023] Olympus Medical Systems Corporation Warning Letter (Hachioji-shi) [12/12/2022] Aizu Olympus Warning Letter [11/02/2022] Infections Associated with Reprocessed Duodenoscopes [06/30/2022] Infections Associated with Reprocessed Urological Endoscopes - Letter to Health Care Providers [04/01/2021]

    关注理由：这条呼吸病学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。

  2. FDA · MedWatch Safety Alerts

    儿科学：Early Alert: Cardinal Health Updates Use Instructions for Presource Packs Containing BD Alaris Pump Infusion Sets

    原文摘录：CDRH is issuing this Early Alert to notify the public of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. … Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    关注理由：这条儿科学资料涉及具体临床问题，研究人群、方法和结局指标可以结合原文进一步查看。

10月16日周五
  1. EMA · News and Safety Reviews

    内分泌与代谢：Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026

    原文摘录：Image credit: © Marcos Osorio/Stocksy | stock.adobe.com Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16 October 2026 Six new medicines recommended for approval; another five medicines recommended for … eu All other enquiries please submit your request via the online form Follow us on Bluesky Related medicine information Foundayo Rasonque Yuviwel Fovlussea Neuzafy Kizfizo Kyinsu Talvey Tukysa Tryngolza Yartemlea Mylotarg Truqap Ibrance

    关注理由：这条内分泌与代谢资料涉及具体临床问题，研究人群、方法和结局指标可以结合原文进一步查看。

  2. WHO · Disease Outbreak News OData

    感染病学：Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia

    原文摘录：Disease Outbreak News Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia 15 October 2026 See all DONs related to this event Situation at a glance Between 1 January and 5 October 2026, the Kingdom of Saudi Arabia reported eight laborato … int/emergencies/disease-outbreak-news/item/2026-DON618 See all DONs related to this event

10月15日周四
  1. EMA · News and Safety Reviews

    肿瘤学：EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

    原文摘录：Image credit: © Chinnapong | stock.adobe.com EMA recommends authorisation of Rasonque for metastatic pancreatic cancer 15 October 2026 Phased review fast tracks assessment of medicine addressing unmet medical need News Human Innovation Medicines EMA’s hum … eu All other enquiries Please submit your request via the online form Follow us on Bluesky Related medicine information Rasonque

    关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。

10月9日周五
  1. PubMed / NCBI E-utilities

    妇产科学：Influence of perineal tears and body image disturbance on postpartum sexual quality of life: a cross-sectional study.

    原文摘录：BACKGROUND: Whether perineal injury severity independently determines postpartum sexual quality of life (SQoL) is unclear. This study evaluated perineal tears and body image as determinants of SQoL and sexual resumption timing. … OASI carries a substantial risk of delayed sexual resumption, warranting dedicated postpartum counseling

10月7日周三
10月1日周四
  1. Europe PMC · 撤稿与关系监测

    外科与麻醉：Withdrawn as duplicate: Pulmonary Blood Volumes on CT Predict Residual Pulmonary Hypertension Post-Pulmonary Endarterectomy.

    原文摘录：Pulmonary blood volumes (PBV), currently not assessed by computed tomography pulmonary angiography (CTPA), could provide additional information to routine investigations performed for chronic thromboembolic pulmonary hypertension (CTEPH). … Utilizing CTPA-derived PBV post-PEA to identify patients without residual PH can potentially reduce the need for routine postoperative right heart catheterization

9月14日周一
  1. 中国医学科学院／北京协和医学院 · 院校报道

    中国医学科学院血液病医院程涛、朱平、高欣团队在Protein & Cell在线发表人类生命全程血细胞单细胞转录组图谱研究并构建泛血液肿瘤预后评估框架

    中国医学科学院血液病医院程涛、朱平、高欣团队2026年9月8日在Protein & Cell在线发表研究（DOI:10.1093/procel/pwag064），整合约百万个单细胞转录组数据，基于覆盖胎儿至老年五个生命阶段的207例健康个体，构建涵盖96个血细胞亚群的生命全程血液细胞图谱。